These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1426 related items for PubMed ID: 18698014

  • 1. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 2. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 3. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 4. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [Abstract] [Full Text] [Related]

  • 5. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.
    J Nephrol; 2008 Aug; 21(6):826-35. PubMed ID: 19034866
    [Abstract] [Full Text] [Related]

  • 7. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT.
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [Abstract] [Full Text] [Related]

  • 8. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [Abstract] [Full Text] [Related]

  • 9. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B.
    Curr Med Res Opin; 2006 Dec; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [Abstract] [Full Text] [Related]

  • 10. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.
    Am J Ther; 2008 Dec; 15(6):506-11. PubMed ID: 19127132
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM, Raskin P.
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [Abstract] [Full Text] [Related]

  • 12. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 13. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC.
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [Abstract] [Full Text] [Related]

  • 14. Review article: Thiazolidinediones and heart failure.
    Chaggar PS, Shaw SM, Williams SG.
    Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
    [Abstract] [Full Text] [Related]

  • 15. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 16. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J, Scheen AJ.
    Rev Med Suisse; 2007 Aug 29; 3(122):1876, 1878-83. PubMed ID: 17896661
    [Abstract] [Full Text] [Related]

  • 17. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ.
    Fundam Clin Pharmacol; 2009 Dec 29; 23(6):675-9. PubMed ID: 19744248
    [Abstract] [Full Text] [Related]

  • 18. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
    Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.
    J Clin Pharmacol; 2011 Feb 29; 51(2):173-80. PubMed ID: 20484611
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC.
    J Pharm Pharmacol; 2008 Dec 29; 60(12):1573-82. PubMed ID: 19000361
    [Abstract] [Full Text] [Related]

  • 20. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.
    Diabetes Obes Metab; 2008 Dec 29; 10(12):1221-38. PubMed ID: 18505403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.